Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
Abstract: M184V (8.4%, 20/239) and K103N (5.4%, 13/239) were the most prevalent mutations.
Result: M184V (8.4%, 20/239) and K103N (5.4%, 13/239) were the most frequent NRTI- and NNRTI-associated mutations respectively.
Result: The most common patterns among ART-experience patients were K103N only or in combination with P225H or V106A (9.8%, 4/41), Y181C only or in combin
Table: K103N
Discussion: K103N also was the most prevalent NNRTI mutation and is responsible for cross-resistance in this drug class.
Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia.
Result: Forward transmission of SDRMs throughout the period 2014-2017 was determined in several TCs: (1) T215S (n = 20) and its sub-cluster T215S + L210W (n = 9) (2), K101E (n = 14) and (3) V32I + I47V + T215D/E + L100I + K103N (n = 8).
Result: Resistance to NNRTIs was determined in 27/403 (6.7%) cases, with mutations K101E (3.7%), K103N (2.5%) and L100I (1.9%) most frequently observed.
Result: Some of these sequences carrying SDRMs: T69D, G190E, K219Q and
Survey of Pretreatment HIV Drug Resistance and Genetic Transmission Network Analysis Among HIV Patients in a High Drug-Use Area of Southwest China.
Result: Among the 119 NNRTI mutations identified, the most common mutation was K103N (45.5%), which can cause a high level of resistance to efavirenz (EFV) and nevirapine (NVP), the two ARV drugs that are the components of the WHO-recommended first-line regimens.
Result: Among them, the most common drug resistance mutation was K103N, and a total of 12 HIV infection patients contained this drug resistance mutation and were distributed in 10 transmission clusters.
Discussion:
Discussion: EFV and NVP, which are both NNRTIs, had the highest drug resistance rate in this study which was mainly caused by K103N, V179D, V106M and E138G/Q mutations.
Delayed linkage to HIV care among asylum seekers in Quebec, Canada.
Abstract: One-fifth (21%) had baseline resistance to at least one antiretroviral agent; the K103 N/S mutation was the most common mutation.
Method: The proportion of patients with M184 V/I, K103 N/S, and K65R mutations, as well as the presence of thymidine analogue mutations (TAMs) were also reported.
Result: Baseline resistance to at least one NNRTI was the most commonly observed resistance (with 12% of newly diagnosed asylum seekers exhibiting K103 N/S mutations; of these, 5/7 were from Latin America and 2/7 were from Africa), followed by NRTI resistance.
Discussion: In fact, among the seven newly diagnosed individuals with a K103 N/S mutation, three were wome
HIV-1 Reverse Transcriptase Promotes Tumor Growth and Metastasis Formation via ROS-Dependent Upregulation of Twist.
PMID: 31885806
2019
Oxidative medicine and cellular longevity
Result: Based on this, we designed RT_A with M184V and K65R/N (RT_An) and RT_A with
Discussion: As expected, the consensus RT_A was enzymatically active, RT-An (K65R/M184 V) was compromised in the polymerase, and RT_Ann (K103N/G190S), in the RNase H activities.
Discussion: We designed the consensus RT of HIV-1 clade A FSU_A strain (RT_A) and two RT_A variants with primary mutations of resistance to NRTI (K65R and M184V; RT_An) and NNRTI (K103N and G190S; RT_Ann).
Identification of novel bifunctional HIV-1 reverse transcriptase inhibitors.
PMID: 29029095
2018
The Journal of antimicrobial chemotherapy
Abstract: Optimization of compound A led to more potent analogues, which retained similar activities against WT and K103N mutant viruses with submicromolar potency in a cell-based assay.
Abstract: RESULTS: Compound A displayed equal or greater potency against many common NNRTI-resistant RTs (K103N and Y181C RTs) relative to WT RT.
Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy.
PMID: 29084434
2018
AIDS research and human retroviruses
Introduction: In this population, Y181C was more common in NVP-exposed patients, whereas K103N, V108I, and P225H were more common in EFV-exposed patients (p < .001).
Introduction: The most common mutations detected were Y181C, K103N, G190A, A98G, K101E, V108I, H221Y, M230L, and P225H.
Paper-based detection of HIV-1 drug resistance using isothermal amplification and an oligonucleotide ligation assay.
Method: The selected primers amplify a 338-base-pair region (nt 2810 to 3147) of the pol gene that contains the resistance mutations M184V, K103N, Y181C, and V106M.
Discussion: Although an OLA can detect only one mutation at a time, the fragment of HIV pol amplified in this work contains several other high-profile mutations including K103N, Y181C, and V106M.
Discussion: Cross sectional data suggests that the four mutations M184V, K103N, Y181C, and V106M would identify at least 90% of patients with resistance on a first-line r
Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.
Result: Among the NNRTI failure patients, two patients had K103N and V106M/Y188CH mutation respectively.
Result: None of the INSTI-naive subjects had NRTI mutations; however, three individuals had NNRTIs DRM (V106M, K103N, G190A).
Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
Abstract: Among them, the most promising N1-aryl-2-arylthioacetamido-benzimidazoles and N1-aryl-2-aryloxyacetamido-benzimidazoles were also tested toward a panel of single- and double-mutants strain responsible for resistance to NNRTIs, showing in vitro antiviral activity toward single mutants L100I, K103N, Y181C, Y188L and E138K.
HIV mutation literature information.
PMID: 
2019
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT